Generali Asset Management SPA SGR Has $1.48 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Generali Asset Management SPA SGR increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6,368.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,234 shares of the biopharmaceutical company’s stock after buying an additional 3,184 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Alnylam Pharmaceuticals were worth $1,475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Salomon & Ludwin LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $27,000. Hilltop National Bank bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $41,000. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $30,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $37,000. Finally, Ameritas Advisory Services LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $42,000. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the sale, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the completion of the sale, the chief executive officer directly owned 65,409 shares of the company’s stock, valued at approximately $29,517,119.43. This trade represents a 13.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 37,778 shares of company stock valued at $17,096,988 in the last quarter. 1.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ALNY. Bank of America lifted their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. JPMorgan Chase & Co. lowered their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Piper Sandler reiterated an “overweight” rating and issued a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Finally, Evercore ISI boosted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Twenty-three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $477.44.

Alnylam Pharmaceuticals Trading Up 0.6%

Shares of ALNY stock opened at $400.17 on Monday. The company has a market cap of $52.87 billion, a P/E ratio of 1,667.38 and a beta of 0.32. The stock has a 50 day simple moving average of $432.07 and a two-hundred day simple moving average of $418.13. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.